1200P BrigALK2 study: A multicentric real-world study evaluating brigatinib in ALK positive advanced pre-treated non-small cell lung cancers: Long-term follow-up with focus on lorlatinib efficacy after brigatinib
| Autor: | Descourt, R., Pérol, M., Rousseau-Bussac, G., Planchard, D., Mennecier, B., Wislez, M., Cadranel, J., Cortot, A.B., Guisier, F., Galland, L., Do, P., Schott, R., Dansin, E., Arrondeau, J., Auliac, J.B., Chouaid, C. |
|---|---|
| Zdroj: | In Annals of Oncology September 2021 32 Supplement 5:S958-S958 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|